Theriva Biologics, Inc., a clinical-stage company focused on developing cancer therapeutics, reported its financial results for the year ended December 31, 2025. The company incurred a net loss of $23.7 million, compared to a net loss of $25.7 million in the previous year. General and administrative expenses increased significantly to $15.4 million, primarily due to a $9.0 million contingent consideration adjustment related to the positive topline data from the VIRAGE Phase 2b clinical trial of VCN-01 in pancreatic cancer. Research and development expenses decreased to $8.6 million, reflecting lower clinical trial expenses as the VIRAGE trial concluded and the Phase 1b/2a trial of SYN-004 progressed.
A key strategic development for Theriva Biologics was the execution of a license agreement with Rasayana Therapeutics, Inc. in February 2026, granting Rasayana exclusive worldwide rights to research, develop, manufacture, and commercialize products related to SYN-020. This agreement included an upfront payment of $300,000 to Theriva Biologics, with potential for up to $16.0 million in development milestone payments and $22.0 million in sales milestone payments, as well as tiered royalties on net sales. As part of its strategic shift towards oncology, the company is also exploring options for its SYN-004 asset, including out-licensing or partnering.
Operationally, Theriva Biologics completed patient enrollment in the VIRAGE Phase 2b clinical trial and announced positive topline data, showing improvements in overall survival, progression-free survival, and duration of response in patients treated with VCN-01 plus standard-of-care chemotherapy. The company also received additional Scientific Advice from the European Medicines Agency (EMA) on the design of a Phase 3 clinical trial for VCN-01 in metastatic pancreatic ductal adenocarcinoma. In September 2025, the company implemented a workforce reduction of 32% to focus resources on key activities, which is expected to save approximately $1.8 million annually.
Looking ahead, Theriva Biologics anticipates that its current cash reserves will fund operations into the first quarter of 2027, supporting overhead costs, clinical trial closeout, manufacturing scale-up, regulatory interactions, and preclinical studies. However, the company acknowledges that additional funding will be required for future clinical trials and that there is no guarantee such funding will be available on acceptable terms. The company's auditor's report contains an explanatory paragraph regarding the company's ability to continue as a going concern, highlighting the need for additional capital to sustain operations.
About Theriva Biologics, Inc.
Theriva Biologics is a clinical-stage biotech developing cancer therapeutics, notably oncolytic viruses like VCN-01 for solid tumors and pancreatic cancer. Its platform leverages virus-induced tumor cell destruction and immune activation, with potential for intravenous delivery. The company also explores microbiome-focused therapies for infections like C. difficile and VRE, aiming to address high unmet medical needs in oncology and infectious diseases.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.